SynthesisAmerican journal of Alzheimer's disease and other dementias2011
A review of the methods used to estimate the cost of Alzheimer's disease in the United States.
Synthesis in American journal of Alzheimer's disease and other dementias, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review.BMJ global health · 2022Pooled it
- How relevant are social costs in economic evaluations? The case of Alzheimer's disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Cost of dementia in Medicare managed care: a systematic literature review.The American journal of managed care · 2019Pooled it
- Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies.PharmacoEconomics · 2021Article
- Article
- Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations.Alzheimer's research & therapy · 2018Review
- Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?PharmacoEconomics · 2016Article
- Cost-of-Illness Studies: An Updated Review of Current Methods.PharmacoEconomics · 2016Review
- Comparison of informal care time and costs in different age-related dementias: a review.BioMed research international · 2013Review
- Methodological considerations in cost of illness studies on Alzheimer disease.Health economics review · 2012Article
- Road to the nursing home: costs and disease progression among medicare beneficiaries with ADRD.American journal of Alzheimer's disease and other dementias · 2012Article
- Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease.PloS one · 2012Article
- Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.Alzheimer disease and associated disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledBACKGROUN/RATIONALE: To determine the suitability of published estimates of the US cost of Alzheimer's disease (AD) for use in cost-effectiveness models for new AD treatments.
methodsA systematic literature review of published information on direct medical, direct nonmedical, indirect, and informal care costs for different levels of disease severity.
resultsNineteen studies were included in the review. In studies presenting mean costs by disease severity, the change in different types of costs with increasing disease severity varied, depending on the data sources and characteristics of patients with AD. In studies presenting the results of regression analyses, costs were shown to be independently associated with cognition, functional status, behavioral symptoms, and dependence.
conclusionsPublished US studies (1) did not include all the types of costs and AD populations, and (2) generally did not include all the measures of disease severity that are needed for cost-effectiveness models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.